Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413248 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL17345285 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7324091 | 0.86 | CTSK (0.57) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7324089 | 0.86 | CTSK (0.57) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10192146 | 0.86 | CTSK (0.57) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23100865 | 0.85 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10280834 | 0.85 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16710007 | 0.85 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20825614 | 0.85 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1312767 | 0.85 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469665-B2 | Compound having lysophosphatidylserine receptor function modulation activity | THE UNIVERSITY OF TOKYO (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150361119-A1 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY | TOHOKU UNIVERSITY (JP) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361119-A1 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY | LPAR1, LPAR3, LPAR2 | CTSK 2800/4885CTSS 2064/4885CA1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.